PCVX Straddle Strategy
PCVX (Vaxcyte, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX (Vaxcyte, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $7.83B, a beta of 1.30 versus the broader market, a 52-week range of 29-65, average daily share volume of 1.4M, a public-listing history dating back to 2020, approximately 414 full-time employees. These structural characteristics shape how PCVX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.30 indicates PCVX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on PCVX?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current PCVX snapshot
As of May 15, 2026, spot at $52.69, ATM IV 52.10%, IV rank 39.06%, expected move 14.94%. The straddle on PCVX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on PCVX specifically: PCVX IV at 52.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 14.94% (roughly $7.87 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PCVX expiries trade a higher absolute premium for lower per-day decay. Position sizing on PCVX should anchor to the underlying notional of $52.69 per share and to the trader's directional view on PCVX stock.
PCVX straddle setup
The PCVX straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PCVX near $52.69, the first option leg uses a $52.69 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PCVX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PCVX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $52.69 | N/A |
| Buy 1 | Put | $52.69 | N/A |
PCVX straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
PCVX straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on PCVX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on PCVX
Straddles on PCVX are pure-volatility plays that profit from large moves in either direction; traders typically buy PCVX straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
PCVX thesis for this straddle
The market-implied 1-standard-deviation range for PCVX extends from approximately $44.82 on the downside to $60.56 on the upside. A PCVX long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current PCVX IV rank near 39.06% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on PCVX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, PCVX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PCVX-specific events.
PCVX straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PCVX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PCVX alongside the broader basket even when PCVX-specific fundamentals are unchanged. Always rebuild the position from current PCVX chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on PCVX?
- A straddle on PCVX is the straddle strategy applied to PCVX (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With PCVX stock trading near $52.69, the strikes shown on this page are snapped to the nearest listed PCVX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PCVX straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the PCVX straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 52.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PCVX straddle?
- The breakeven for the PCVX straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PCVX market-implied 1-standard-deviation expected move is approximately 14.94%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on PCVX?
- Straddles on PCVX are pure-volatility plays that profit from large moves in either direction; traders typically buy PCVX straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current PCVX implied volatility affect this straddle?
- PCVX ATM IV is at 52.10% with IV rank near 39.06%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.